Share：
Share this content in WeChat
X
[Chinese][PDF]13722
• Review •
Application and progression of magnetic resonance imaging VI-RADS score in bladder cancer
WANG Chengyan  LIU Huaqiong  GAO Wenxin  JIANG Xingyue  XU Chang 

WANG C Y, LIU H Q, GAO W X, et al. Application and progression of magnetic resonance imaging VI-RADS score in bladder cancer[J]. Chin J Magn Reson Imaging, 2023, 14(8): 176-181. DOI:10.12015/issn.1674-8034.2023.08.031.


[Abstract] Bladder cancer is the most common urinary malignant tumor, because it is difficult to accurately classify and stage it, which makes the diagnosis and treatment of bladder cancer patients face many problems. With the continuous development and improvement of modern medical technology. In 2018, the Vesical Imaging-Reporting and Data System (VI-RADS) based on multi-parametric magnetic resonance imaging (mpMRI) technology has been recognized by the Japanese Society of Abdominal Radiology, European Association of Urological and European Society of Urology Imaging. The VI-RADS score can classify bladder cancer more accurately and provide guidance for clinicians in the treatment of patients with bladder cancer. This article reviews the research status and progress of VI-RADS in bladder cancer, VI-RADS parameters and the selection of the optimal cut-off value for the diagnosis of bladder cancer, and the combination of VI-RADS and radiomics, and looks forward to future research directions such as tumor size and tumor location on VI-RADS, aiming to provide reference for research in this field.
[Keywords] bladder cancer；myometrial invasion；Vesical Imaging-Reporting and Data System；magnetic resonance imaging；multi-parametric magnetic resonance imaging；clinical staging

WANG Chengyan   LIU Huaqiong   GAO Wenxin   JIANG Xingyue   XU Chang*  

Department of Radiology, Binzhou Medical University Hospital, Binzhou 256603, China

Corresponding author: Xu C, E-mail: xuchang3183@126.com

Conflicts of interest   None.

Received  2022-12-09
Accepted  2023-05-06
DOI: 10.12015/issn.1674-8034.2023.08.031
WANG C Y, LIU H Q, GAO W X, et al. Application and progression of magnetic resonance imaging VI-RADS score in bladder cancer[J]. Chin J Magn Reson Imaging, 2023, 14(8): 176-181. DOI:10.12015/issn.1674-8034.2023.08.031.

[1]
LIU Y, ZHENG H J, XU X P, et al. The invasion depth measurement of bladder cancer using T2-weighted magnetic resonance imaging[J/OL]. Biomed Eng Online, 2020, 19(1): 92 [2022-10-14]. https://pubmed.ncbi.nlm.nih.gov/33287834/. DOI: 10.1186/s12938-020-00834-8.
[2]
BABJUK M, BÖHLE A, BURGER M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016[J]. Eur Urol, 2017, 71(3): 447-461. DOI: 10.1016/j.eururo.2016.05.041.
[3]
GHANDOUR R, SINGLA N, LOTAN Y. Treatment options and outcomes in nonmetastatic muscle invasive bladder cancer[J]. Trends Cancer, 2019, 5(7): 426-439. DOI: 10.1016/j.trecan.2019.05.011.
[4]
WONG V K, GANESHAN D, JENSEN C T, et al. Imaging and management of bladder cancer[J/OL]. Cancers, 2021, 13(6): 1396 [2022-10-14]. https://pubmed.ncbi.nlm.nih.gov/33808614/. DOI: 10.3390/cancers13061396.
[5]
PATEL V G, OH W K, GALSKY M D. Treatment of muscle-invasive and advanced bladder cancer in 2020[J]. CA A Cancer J Clin, 2020, 70(5): 404-423. DOI: 10.3322/caac.21631.
[6]
WANG Y C, SHEN Y Q, HU X M, et al. Application of R2* and apparent diffusion coefficient in estimating tumor grade and T category of bladder cancer[J]. Am J Roentgenol, 2020, 214(2): 383-389. DOI: 10.2214/ajr.19.21668.
[7]
JAZAYERI S B, DEHGHANBANADAKI H, HOSSEINI M, et al. Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: a systematic review and diagnostic meta-analysis[J]. Urol Oncol Semin Orig Investig, 2022, 40(2): 45-55. DOI: 10.1016/j.urolonc.2021.11.008.
[8]
LUO C, HUANG B, WU Y K, et al. Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis[J].Eur Radiol, 2020, 30(8): 4606-4614. DOI: 10.1007/s00330-020-06802-z.
[9]
PANEBIANCO V, NARUMI Y, ALTUN E, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system)[J]. Eur Urol, 2018, 74(3): 294-306. DOI: 10.1016/j.eururo.2018.04.029.
[10]
FENG C, WANG Y C, DAN G Y, et al. Evaluation of a fractional-order calculus diffusion model and bi-parametric VI-RADS for staging and grading bladder urothelial carcinoma[J].Eur Radiol, 2022, 32(2): 890-900. DOI: 10.1007/s00330-021-08203-2.
[11]
BABJUK M, BURGER M, COMPÉRAT E M, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update[J]. Eur Urol, 2019, 76(5): 639-657. DOI: 10.1016/j.eururo.2019.08.016.
[12]
CUMBERBATCH M G K, FOERSTER B, CATTO J W F, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review[J]. Eur Urol, 2018, 73(6): 925-933. DOI: 10.1016/j.eururo.2018.02.014.
[13]
UENO Y, TAKEUCHI M, TAMADA T, et al. Diagnostic accuracy and interobserver agreement for the vesical imaging-reporting and data system for muscle-invasive bladder cancer: a multireader validation study[J]. Eur Urol, 2019, 76(1): 54-56. DOI: 10.1016/j.eururo.2019.03.012.
[14]
DE PERROT T, SADJO ZOUA C, GLESSGEN C G, et al. Diffusion-weighted MRI in the genitourinary system[J/OL]. J Clin Med, 2022, 11(7): 1921 [2022-10-14]. https://pubmed.ncbi.nlm.nih.gov/35407528/. DOI: 10.3390/jcm11071921.
[15]
ABOUELKHEIR R T, ABDELHAMID A, ABOU EL-GHAR M, et al. Imaging of bladder cancer: standard applications and future trends[J/OL]. Medicina, 2021, 57(3): 220 [2022-10-14]. https://pubmed.ncbi.nlm.nih.gov/33804350/. DOI: 10.3390/medicina57030220.
[16]
WOO S M, SUH C H, KIM S Y, et al. Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: a systematic review and meta-analysis[J]. Eur J Radiol, 2017, 95: 46-55. DOI: 10.1016/j.ejrad.2017.07.021.
[17]
GANDHI N, KRISHNA S, BOOTH C M, et al. Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis[J]. BJU Int, 2018, 122(5): 744-753. DOI: 10.1111/bju.14366.
[18]
VAN DER POL C B, SAHNI V A, EBERHARDT S C, et al. ACR appropriateness criteria® PretreatmentStaging of muscle-invasive BladderCancer[J]. J Am Coll Radiol, 2018, 15(5): S150-S159. DOI: 10.1016/j.jacr.2018.03.020.
[19]
WONG B S, DURAN C H, WILLIAMS S B. Vesical imaging reporting and data system (VI-RADS) and impact on identifying depth of invasion with subsequent management in bladder cancer patients: ready for prime time?[J]. Transl Androl Urol, 2020, 9(6): 2467-2470. DOI: 10.21037/tau-20-839.
[20]
SÉGUIER D, PUECH P, KOOL R, et al. Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications[J/OL]. Ther Adv Urol, 2021, 13: 17562872211039583 [2022-10-15]. https://pubmed.ncbi.nlm.nih.gov/34457041/. DOI: 10.1177/17562872211039583.
[21]
ERKOC M, OTUNCTEMUR A, BOZKURT M, et al. The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer[J/OL]. Int J Clin Pract, 2021, 75(9): e14584 [2022-10-17]. https://pubmed.ncbi.nlm.nih.gov/34185372/. DOI: 10.1111/ijcp.14584.
[22]
ARITA Y, SHIGETA K, AKITA H, et al. Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions[J].Eur Radiol, 2021, 31(2): 875-883. DOI: 10.1007/s00330-020-07153-5.
[23]
WANG Z Y, SHANG Y Y, LUAN T, et al. Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer[J/OL]. Cancer Imaging, 2020, 20(1): 26 [2022-10-17]. https://pubmed.ncbi.nlm.nih.gov/32252816/. DOI: 10.1186/s40644-020-00304-3.
[24]
HUANG L, KONG Q C, LIU Z Z, et al. The diagnostic value of MR imaging in differentiating T staging of bladder cancer: a meta-analysis[J]. Radiology, 2018, 286(2): 502-511. DOI: 10.1148/radiol.2017171028.
[25]
JURI H, HIGASHIYAMA A, YAMAMOTO K, et al. Comparison of reduced field-of-view DWI and full field-of view DWI for the differentiation between non-muscle invasive bladder cancer and muscle invasive bladder cancer using VI-RADS[J/OL]. PLoS One, 2022, 17(7): e0271470 [2022-10-18]. https://pubmed.ncbi.nlm.nih.gov/35857788/. DOI: 10.1371/journal.pone.0271470.
[26]
MESSINA E, PISCIOTTI M L, PECORARO M, et al. The use of MRI in urothelial carcinoma[J]. Curr Opin Urol, 2022, 32(5): 536-544. DOI: 10.1097/mou.0000000000001011.
[27]
PIZZI A D, MASTRODICASA D, TARASCHI A, et al. Conspicuity and muscle-invasiveness assessment for bladder cancer using VI-RADS: a multi-reader, contrast-free MRI study to determine optimal b-values for diffusion-weighted imaging[J]. Abdom Radiol, 2022, 47(5): 1862-1872. DOI: 10.1007/s00261-022-03490-9.
[28]
BARCHETTI G, SIMONE G, CERAVOLO I, et al. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center[J].Eur Radiol, 2019, 29(10): 5498-5506. DOI: 10.1007/s00330-019-06117-8.
[29]
WANG H J, LUO C, ZHANG F, et al. Multiparametric MRI for bladder cancer: validation of VI-RADS for the detection of detrusor muscle invasion[J]. Radiology, 2019, 291(3): 668-674. DOI: 10.1148/radiol.2019182506.
[30]
LIU S H, XU F J, XU T Y, et al. Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer[J]. Transl Androl Urol, 2020, 9(2): 445-451. DOI: 10.21037/tau.2020.02.16.
[31]
HONG S B, LEE N K, KIM S, et al. Vesical imaging-reporting and data system for multiparametric MRI to predict the presence of muscle invasion for bladder cancer[J]. J Magn Reson Imaging, 2020, 52(4): 1249-1256. DOI: 10.1002/jmri.27141.
[32]
FRAGKOULIS C, GLYKAS I, PAPADOPOULOS G, et al. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application[J/OL]. Br J Radiol, 2020, 93(1109): 20200025 [2022-10-19]. https://pubmed.ncbi.nlm.nih.gov/31573328/. DOI: 10.1259/bjr.20200025.
[33]
MARCHIONI M, PRIMICERI G, DELLI PIZZI A, et al. Could bladder multiparametric MRI be introduced in routine clinical practice? role of the new VI-RADS score: results from a prospective study[J/OL]. Clin Genitourin Cancer, 2020, 18(5): 409-415.e1 [2022-10-19]. https://www.clinical-genitourinary-cancer.com/article/S1558-7673(20)30051-3/fulltext. DOI: 10.1016/j.clgc.2020.03.002.
[34]
AKCAY A, YAGCI A B, CELEN S, et al. VI-RADS score and tumor contact length in MRI: a potential method for the detection of muscle invasion in bladder cancer[J]. Clin Imaging, 2021, 77: 25-36. DOI: 10.1016/j.clinimag.2021.02.026.
[35]
TAGUCHI S, TAMBO M, WATANABE M, et al. Prospective validation of vesical imaging-reporting and data system using a next-generation magnetic resonance imaging scanner-is denoising deep learning reconstruction useful?[J]. J Urol, 2021, 205(3): 686-692. DOI: 10.1097/ju.0000000000001373.
[36]
DELLI P A, MASTRODICASA D, MARCHIONI M, et al. Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach[J]. Eur Radiol, 2021, 31(6): 3874-3883. DOI: 10.1007/s00330-020-07473-6.
[37]
ELSHETRY A S F, EL-FAWAKRY R M, HAMED E M, et al. Diagnostic accuracy and discriminative power of biparametric versus multiparametric MRI in predicting muscle-invasive bladder cancer[J/OL]. Eur J Radiol, 2022, 151: 110282 [2022-10-19]. https://www.ejradiology.com/article/S0720-048X(22)00132-2/fulltext. DOI: 10.1016/j.ejrad.2022.110282.
[38]
WATANABE M, TAGUCHI S, MACHIDA H, et al. Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field[J]. Eur Radiol, 2022, 32(11): 7513-7521. DOI: 10.1007/s00330-022-08813-4.
[39]
ASLAN S, CAKIR I M, OGUZ U, et al. Comparison of the diagnostic accuracy and validity of biparametric MRI and multiparametric MRI-based VI-RADS scoring in bladder cancer; is contrast material really necessary in detecting muscle invasion?[J].Abdom Radiol, 2022, 47(2): 771-780. DOI: 10.1007/s00261-021-03383-3.
[40]
MENG X Y, HU H L, WANG Y C, et al. Accuracy and challenges in the vesical imaging-reporting and data system for staging bladder cancer[J]. J Magn Reson Imaging, 2022, 56(2): 391-398. DOI: 10.1002/jmri.28064.
[41]
YE L, CHEN Y T, XU H, et al. Biparametric magnetic resonance imaging assessment for detection of muscle-invasive bladder cancer: a systematic review and meta-analysis[J].Eur Radiol, 2022, 32(9): 6480-6492. DOI: 10.1007/s00330-022-08696-5.
[42]
DEL GIUDICE F D, PECORARO M, VARGAS H A, et al. Systematic review and meta-analysis of vesical imaging-reporting and data system (VI-RADS) inter-observer reliability: an added value for muscle invasive bladder cancer detection[J/OL]. Cancers, 2020, 12(10): 2994 [2022-10-18]. https://pubmed.ncbi.nlm.nih.gov/33076505/. DOI: 10.3390/cancers12102994.
[43]
FENG Y B, ZHONG K, CHEN R, et al. Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) for the detection of muscle-invasive bladder cancer: a meta-analysis[J].Abdom Radiol, 2022, 47(4): 1396-1405. DOI: 10.1007/s00261-022-03449-w.
[44]
MENG X Y, HU H L, WANG Y C, et al. Application of bi-planar reduced field-of-view DWI (rFOV DWI) in the assessment of muscle-invasiveness of bladder cancer[J/OL]. Eur J Radiol, 2021, 136: 109486 [2022-09-24]. https://pubmed.ncbi.nlm.nih.gov/33434861/. DOI: 10.1016/j.ejrad.2020.109486.
[45]
AHN H, HWANG S I, LEE H J, et al. Quantitation of bladder cancer for the prediction of muscle layer invasion as a complement to the vesical imaging-reporting and data system[J].Eur Radiol, 2021, 31(3): 1656-1666. DOI: 10.1007/s00330-020-07224-7.
[46]
WANG X Y, TU N, SUN F, et al. Detecting muscle invasion of bladder cancer using a proposed magnetic resonance imaging strategy[J]. J Magn Reson Imaging, 2021, 54(4): 1212-1221. DOI: 10.1002/jmri.27676.
[47]
ZHENG Z T, XU F J, GU Z R, et al. Combining multiparametric MRI radiomics signature with the vesical imaging-reporting and data system (VI-RADS) score to preoperatively differentiate muscle invasion of bladder cancer[J/OL]. Front Oncol, 2021, 11: 619893 [2022-09-27]. https://pubmed.ncbi.nlm.nih.gov/34055600/. DOI: 10.3389/fonc.2021.619893.
[48]
EL-KARAMANY T M, AL-ADL A M, HOSNY M M, et al. Clinical utility of vesical imaging-reporting and data system (VI-RADS) in non-muscle invasive bladder cancer (NMIBC) patients candidate for en-bloc transurethral resection: a prospective study[J/OL]. Urol Oncol Semin Orig Investig, 2022, 40(10): 454.e1-454.e7 [2022-09-28]. https://pubmed.ncbi.nlm.nih.gov/35466036/. DOI: 10.1016/j.urolonc.2022.03.008.
[49]
KUFUKIHARA R, KIKUCHI E, SHIGETA K, et al. Diagnostic performance of the vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical settings: comparison with diagnostic cystoscopy[J/OL]. Urol Oncol Semin Orig Investig, 2022, 40(2): 61.e1-61.e8 [2022-09-30]. https://pubmed.ncbi.nlm.nih.gov/34332846/. DOI: 10.1016/j.urolonc.2021.07.005.
[50]
UENO Y, TAMADA T, TAKEUCHI M, et al. VI-RADS: multiinstitutional multireader diagnostic accuracy and interobserver agreement study[J]. Am J Roentgenol, 2021, 216(5): 1257-1266. DOI: 10.2214/ajr.20.23604.
[51]
DENG L, ZOU Y J, YANG S Q, et al. VI-RADS based on multi-parametric MRI for the prediction of muscle-invasion in bladder cancer and MRI findings of muscle-invasion in bladder cancer located in ureteral orifice[J]. Chin J Magn Reson Imaging, 2022, 13(7): 121-125. DOI: 10.12015/issn.1674-8034.2022.07.022.

PREV Basic principle of time-dependent diffusion MRI and its application in prostate cancer
NEXT Application progress of MRI-based artificial intelligence in endometrial and cervical cancers
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn